Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443391 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
A Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 20
- Study locations
NCT00443391: Completed Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by AbbVie (prior sponsor, Abbott).
NCT00443391 is a Phase 2 study of Attention Deficit Hyperactivity Disorder that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 141 participants, below the 215-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00443391, a Phase 2 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.
Conditions Studied
Interventions
- DRUG ABT-089
Study Locations (20)
Florida
- Site Reference ID/Investigator# 6112 - Jacksonville
- Site Reference ID/Investigator# 6096 - Maitland
- Site Reference ID/Investigator# 6105 - Tampa
Arizona
- Site Reference ID/Investigator# 6109 - Mesa
- Site Reference ID/Investigator# 6765 - Mesa
California
- Site Reference ID/Investigator# 6100 - Lafayette
- Site Reference ID/Investigator# 6107 - San Diego
Texas
- Site Reference ID/Investigator# 6103 - Austin
- Site Reference ID/Investigator# 6104 - Lake Jackson
Georgia
- Site Reference ID/Investigator# 6094 - Smyrna
Kansas
- Site Reference ID/Investigator# 6111 - Newton
Michigan
- Site Reference ID/Investigator# 6113 - Farmington Hills
Nebraska
- Site Reference ID/Investigator# 6110 - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00443391 record still lists
NCT00443391 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 215-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which ABT-089 is the first listed.
NCT00443391 names 20 study sites across 15 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00443391 about?
NCT00443391 is a clinical study titled "A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)". The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.
What is the current status of trial NCT00443391?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2007-02. Estimated completion is 2008-10.
What conditions does trial NCT00443391 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT00443391?
The interventions under investigation include: ABT-089 (DRUG).
Who is sponsoring clinical trial NCT00443391?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00443391 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00443391's enrollment target sits among peer trials
141 39th of 102 higher than 64 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Stimulant Medication in College Students With ADHD
RECRUITING · Phase 2
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
COMPLETED · Phase 2
-
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia